CRISPR and Type 1 Diabetes

CRISPR technology, a powerful gene-editing tool, holds significant promise for the treatment of Type 1 Diabetes (T1D). Researchers are exploring its potential to modify or replace defective genes responsible for autoimmune attacks on insulin-producing beta cells in the pancreas. One approach involves using CRISPR to correct genetic mutations in the immune system, potentially preventing the immune response that destroys these cells. Another promising application is the use of CRISPR to enhance stem cell therapy, enabling the generation of insulin-producing cells from pluripotent stem cells. While clinical applications are still in early stages, CRISPR's ability to precisely target and edit genes offers hope for a long-term cure, rather than just symptom management, in Type 1 Diabetes.

    Related Conference of CRISPR and Type 1 Diabetes

    June 22-23, 2026

    16th World Congress on Endocrinology and Diabetes

    Paris, France
    July 20-21, 2026

    6th World Congress on Endocrine and Diabetes

    Paris, France
    August 17-18, 2026

    4th World congress and Expo on Diabetes

    Toronto, Canada
    August 20-21, 2026

    6th Annual Summit on Diabetes and Endocrinology

    Paris, France
    September 29-30, 2026

    22nd World Congress on Endocrinology & Diabetes

    Paris, France
    October 20-21, 2026

    32nd World Diabetes & Heart Congress

    Amsterdam, Netherlands
    March 29-30, 2027

    8th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands

    CRISPR and Type 1 Diabetes Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in